PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.

"Declarations Ethics approval and consent to participate: Written informed consents were obtained from enrolled patients. The study was conducted under protocol 2014-0185 approved by the Institutional Review Board of MD Anderson Cancer Center.Consent for publication: Written informed consents including consents for publication were obtained from enrolled patients.Author contributions:Hui Chen: Data curation; Formal analysis; Investigation; Methodology; Writing – original draft.Qingqing Ding: Data curation; Formal analysis; Investigation; Methodology; Writing – review & editing.Laila Khazai: Data curation; Formal analysis; Investigation; Methodology; Writing – review & editing.Li Zhao: Data curation; Formal analysis; Investigation; Methodology; Writing – original draft.Senthil Damodaran: Conceptualization; Investigation; Writing – review & editing.Jennifer K. Litton: Investigation; Writing – review & editing.Gaiane M. Rauch: Investigation; Project administration; Writing – review & editing.Clinton Yam: Data curation; Investigation; Project administration; Writing – review & editing.Jeffrey T. Chang: Investigation; Writing – review & editing.Sahil Seth: Investigation; Methodology; Writing – review & editing.Bora Lim: Investigation; Writing – review & editing.Alastair M. Thompson: Investigation; Writing – review & editing.Elizabeth A. Mittendorf: Investigation; Writing – review & editing.Beatriz Adrada: Investigation; Writing – review & editing.Kiran Virani: Data curation; Investigation; Project administration; Writing – review & editing.Jason B. White: Data curation; Investigation; Project administration; Writing – review & editing.Elizabeth Ravenberg: Data curation; Investigation; Project administration; Writing – review & editing.Xingzhi Song: Investigation; Writing – review & editing.Rosalind Candelaria: Investigation; Writing – review & editing.Banu Arun: Investigation; Writing – review & editing.Naoto T. Ueno: Investigation; Writing – review & editing.Lumarie Santiago: Investigation; Writing – review & editing.Sadia Saleem: Investigation; Writing – review & editing.Sausan Abouharb: Investigation; Writing – review & editing.Rashmi K. Murthy: Investigation; Writing – review & editing.Nuhad Ibrahim: Investigation; Writing – review & editing.Mark J. Routbort: Methodology; Writing – review & editing.Aysegul Sahin: Investigation; Writing – review & editing.Vicente Valero: Investigation; Writing – review & editing.William Fraser Symmans: Investigation; Writing – review & editing.Debu Tripathy: Investigation; Project administration; Writing – review & editing.Wei-Lien Wang: Investigation; Methodology; Writing – review & editing.Stacy Moulder: Conceptualization; Investigation; Methodology; Project administration; Writing – review & editing.Lei Huo: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing – original draft.Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by a CPRIT Multi-Investigator Research Award (MIRA, RP160710), the generous philanthropic contributions to the Moon Shots Program of the University of Texas MD Anderson Cancer Center, as well as the Winterhof and Still Water funds to SM. Funding and drug support were provided (in part) by Amgen Inc.; Astellas Pharma Global Development, Inc.; Genentech, USA Inc.; Novartis AG; and Pfizer Inc.Competing interests: SD reports grant or research support for Guardant Health, Taiho, EMD Serono, Novartis, CPRIT, and Sermonix, and membership on advisory committees or review panels, board membership, etc. with ASCO and ABIM. JKL reports grant or research support form Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, Astro-Zeneca, Medimmune, Zenith, and Merck. She also reports financial relationships with Speaker’s Bureau for MedLearning, Physician’s Education Resource, Prime Oncology, Medscape, Clinical Care Options, Medpage, and royalty from UpToDate. BL reports research funding from Takeda oncology, Merck, Genentech, Puma Biotechnology, NIH, DOD, Chan and Zuckerberg Institute, Adopt a Scientist program. EAM reports compensated service on scientific advisory boards for AstraZeneca, Exact sciences (formerly Genomic Health), Merchk, Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly and Roche/Genentech; and institutional research support from Roche/Genentech (viaSU2C grant) and Gilead. She receives research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor. She also reports uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. RKM has served as a consultant for AstraZeneca, Genentech, Novartis, Pfizer, Puma Biotechnology Sanofi, and Seattle Genetics. She has received research funding from AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Pfizer, and Seattle Genetics. DT reports a research contract that was paid to the institution for Pfizer, Novartis, and Polyphor, as a paid consultant for AstraZeneca, GlaxoSmithKline, OncoPep, Gilead, Novartis, Pfizer, Personalis, and Sermonix.Availability of data and materials: The data used for this study will be made available upon reasonable request from the corresponding author. Competing interests: SD reports grant or research support for Guardant Health, Taiho, EMD Serono, Novartis, CPRIT, and Sermonix, and membership on advisory committees or review panels, board membership, etc. with ASCO and ABIM. JKL reports grant or research support form Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, Astro-Zeneca, Medimmune, Zenith, and Merck. She also reports financial relationships with Speaker’s Bureau for MedLearning, Physician’s Education Resource, Prime Oncology, Medscape, Clinical Care Options, Medpage, and royalty from UpToDate. BL reports research funding from Takeda oncology, Merck, Genentech, Puma Biotechnology, NIH, DOD, Chan and Zuckerberg Institute, Adopt a Scientist program. EAM reports compensated service on scientific advisory boards for AstraZeneca, Exact sciences (formerly Genomic Health), Merchk, Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly and Roche/Genentech; and institutional research support from Roche/Genentech (viaSU2C grant) and Gilead. She receives research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor. She also reports uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. RKM has served as a consultant for AstraZeneca, Genentech, Novartis, Pfizer, Puma Biotechnology Sanofi, and Seattle Genetics. She has received research funding from AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Pfizer, and Seattle Genetics. DT reports a research contract that was paid to the institution for Pfizer, Novartis, and Polyphor, as a paid consultant for AstraZeneca, GlaxoSmithKline, OncoPep, Gilead, Novartis, Pfizer, Personalis, and Sermonix."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by a CPRIT Multi-Investigator Research Award (MIRA, RP160710), the generous philanthropic contributions to the Moon Shots Program of the University of Texas MD Anderson Cancer Center, as well as the Winterhof and Still Water funds to SM. Funding and drug support were provided (in part) by Amgen Inc.; Astellas Pharma Global Development, Inc.; Genentech, USA Inc.; Novartis AG; and Pfizer Inc."

"Trial registration: NCT02276443."